Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 1 of 4 (25%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCER, ANDREA LYNNE MORRIS | 1 | 28.6% | +83.3% |
| MCLEOD, AFRICA MHAIRIE | 1 | 50.0% | +73.0% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 58.9% | +34.1% |
| CONNORS, ALEXANDRA F | 1 | 23.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019393 | ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 8d overdue |
| 18019396 | CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY | SPENCER, ANDREA LYNNE MORRIS | — |
| 17926024 | ENGINEERED PARKIN AND USES THEREOF | DACE DENITO, ALEXANDRA GERALDINE | — |
| 17430107 | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019393 | ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 8d overdue |
| 18019396 | CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY | SPENCER, ANDREA LYNNE MORRIS | — |
| 17926024 | ENGINEERED PARKIN AND USES THEREOF | DACE DENITO, ALEXANDRA GERALDINE | — |
| 17430107 | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE | CONNORS, ALEXANDRA F | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1635 | 1 |
| 1636 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18019396 | CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY | SPENCER, ANDREA LYNNE MORRIS | 1631 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2023 |
| 18019393 | ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 1635 | §101§102§103§112 | Non-Final OA | 8d overdue | AI Ready | Feb 02, 2023 |
| 17926024 | ENGINEERED PARKIN AND USES THEREOF | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102§103§112 | Final Rejection | — | Pending | Nov 17, 2022 |
| 17430107 | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE | CONNORS, ALEXANDRA F | 1634 | §103§112Other | Non-Final OA | — | Pending | Aug 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial